Eccogene
益方生物
Executive Summary
Eccogene is a Shanghai-based biotech with demonstrated partnering capability and innovative small molecule programs, evidenced by their recent ~$1B+ oral GLP-1 licensing deal with AstraZeneca. The company appears focused on metabolic diseases with strong chemistry capabilities and shows clear deal-readiness for out-licensing opportunities. BIOSECURE risk is currently low as they are not designated, making them an attractive potential partner for US pharma seeking Chinese innovation without regulatory barriers.
Structure: Eccogene trades on Shanghai Stock Exchange (688382.SS), indicating it's a domestically-listed Chinese entity likely structured as a PRC company rather than a VIE. Limited subsidiary information suggests either a streamlined structure or incomplete disclosure, requiring deeper due diligence on corporate architecture and IP ownership chains.
Latest Financials
Revenue: 19156299.24, Net Profit: -305306509.72. Source: East Money (688382)
Period: 2024-09-30 | Source: eastmoney
Ownership & Shareholder Structure
Corporate Events
益方生物：益方生物自愿披露关于D-2570在美国获准开展银屑病II期临床试验的公告
CNINFO announcement for Eccogene (688382.SS)
益方生物：益方生物2025年度业绩快报公告
CNINFO announcement for Eccogene (688382.SS)
益方生物：益方生物2026年第一次临时股东会决议公告
CNINFO announcement for Eccogene (688382.SS)
益方生物：君合律师事务所上海分所关于益方生物科技（上海）股份有限公司2026年第一次临时股东会的法律意见书
CNINFO announcement for Eccogene (688382.SS)
益方生物：益方生物关于2026年第一次临时股东会取消部分议案的公告
CNINFO announcement for Eccogene (688382.SS)
AstraZeneca licenses oral GLP-1 from Eccogene
AstraZeneca licensed Eccogene's oral GLP-1 receptor agonist for ~$1B+. Validates Chinese small molecule innovation in the massive obesity/metabolic market.
Eccogene Financial Report
Revenue: 19156299.24, Net Profit: -305306509.72. Source: East Money (688382)
Clinical Trials(8 total)
1
Phase 2
6
Phase 1
1
EARLY_Phase 1
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07334080 | ECC4703 F0 formulation, ECC4703 F1 formulation, ECC4703 F2 formulation, ECC4703 F3 formulation | Ph.1 | RECRUITING | 72 |
| NCT07288138 | Placebo, ECC4703, ECC0509, ECC4703 | Ph.2 | RECRUITING | 160 |
| NCT06988553 | AZD5004, Placebo | Ph.1 | COMPLETED | 45 |
| NCT06293742 | ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin | Ph.1 | COMPLETED | 48 |
| NCT06268145 | ECC5004 | Ph.1 | COMPLETED | 14 |
| NCT05654831 | Placebo, ECC5004 | Ph.1 | COMPLETED | 69 |
| NCT05552274 | ECC4703, Placebo | EARLY_Ph.1 | COMPLETED | 75 |
| NCT05012423 | Placebo, ECC0509, Placebo, ECC0509 | Ph.1 | COMPLETED | 89 |
BIOSECURE Risk
Company is explicitly noted as 'clear' on BIOSECURE status with no BCC designation, and recent major deal with AstraZeneca suggests Western pharma comfort with regulatory risk
Key Exposures:
- •Potential future designation risk if geopolitical tensions escalate
- •Shanghai headquarters in PRC jurisdiction
Mitigation: No specific mitigation efforts identified, but clean current status and successful AstraZeneca partnership suggest manageable risk profile
BD Intelligence
Therapeutic Areas:
Recent Deals: Major validation through ~$1B+ AstraZeneca licensing of oral GLP-1 receptor agonist, demonstrating both innovative chemistry capabilities and willingness to out-license globally
Approach: Approach as high-priority target for metabolic disease partnerships; company has proven deal execution and innovative small molecule platform that could yield multiple opportunities
Red Flags
- ⚠Limited public disclosure on management team raises transparency concerns
- ⚠No subsidiary information available may indicate complex or opaque corporate structure
- ⚠Heavy dependence on single therapeutic area could limit diversification opportunities
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 7
- Gov-Connected
- 0
- Clinical Trials
- 8
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (8 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.